Empowered Funds LLC Takes Position in Cardinal Health, Inc. $CAH

Empowered Funds LLC purchased a new position in Cardinal Health, Inc. (NYSE:CAH) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 103,576 shares of the company’s stock, valued at approximately $24,552,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. LWM Advisors Inc. raised its position in Cardinal Health by 4.4% in the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock worth $244,000 after purchasing an additional 43 shares during the period. Kathmere Capital Management LLC grew its position in shares of Cardinal Health by 1.2% in the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock worth $896,000 after buying an additional 49 shares during the last quarter. Hillsdale Investment Management Inc. increased its position in Cardinal Health by 0.9% during the 4th quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock valued at $1,184,000 after buying an additional 50 shares in the last quarter. V Square Quantitative Management LLC increased its stake in Cardinal Health by 2.6% during the 1st quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock valued at $423,000 after purchasing an additional 50 shares in the last quarter. Finally, Generali Asset Management SPA SGR raised its stake in Cardinal Health by 11.0% in the 4th quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock worth $105,000 after acquiring an additional 51 shares during the last quarter. 87.17% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Deborah Weitzman sold 7,354 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the completion of the transaction, the chief executive officer directly owned 77,901 shares of the company’s stock, valued at $18,341,790.45. The trade was a 8.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jessica L. Mayer sold 29,436 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total value of $6,952,488.84. Following the transaction, the insider directly owned 33,076 shares of the company’s stock, valued at approximately $7,812,220.44. This represents a 47.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 210,271 shares of company stock valued at $49,626,657. Corporate insiders own 0.12% of the company’s stock.

Cardinal Health Stock Down 1.4%

NYSE:CAH opened at $235.01 on Friday. The stock’s fifty day moving average is $232.84 and its two-hundred day moving average is $218.31. Cardinal Health, Inc. has a 52 week low of $145.87 and a 52 week high of $258.30. The company has a market capitalization of $54.66 billion, a P/E ratio of 32.50, a P/E/G ratio of 1.43 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last posted its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts anticipate that Cardinal Health, Inc. will post 12.55 earnings per share for the current fiscal year.

Cardinal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a $0.5158 dividend. This represents a $2.06 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Royal Bank Of Canada initiated coverage on Cardinal Health in a report on Wednesday, August 19th. They set an “outperform” rating and a $276.00 target price for the company. JPMorgan Chase & Co. increased their price target on shares of Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings downgraded Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a research report on Wednesday, August 19th. Mizuho increased their price objective on shares of Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, Leerink Partners set a $292.00 price target on Cardinal Health in a research note on Tuesday, August 11th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $266.56.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.